Clinically significant drug-drug interaction between tacrolimus and phenobarbital: The price we pay

Journal of Pharmacy Practice

Volumn 23, Issue 6, 2010, Pages 585-589

  Siddiqi, Nida ^a   Marfo, Kwaku ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b Montefiore Einstein Transplant Program   (United States)

Author keywords

carbamazepine; drug drug interaction; phenobarbital; tacrolimus

Indexed keywords

BASILIXIMAB; CARBAMAZEPINE; ETIRACETAM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENOBARBITAL; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; SEIZURE;

EID: 78650218243     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010377804     Document Type: Article

References (16)

1. Halloran P. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004 ; 351 (26). 2715-2729.
2. Oellerich M., Armstrong VW, Schutz E., et al. Therapeutic drug monitoring of cyclosporine and tacrolimus. Clin Biochem. 1998 ; 31 (5). 309-316.
3. O'Seaghdha CM, McQuillan R., Moran AM, et al. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection. Clin Transplant. 2009 ; 23 (4). 462-468.
4. Iwasaki K., Shiraga T., Matsuda H., et al. Further metabolism of FK506 (tacrolimus): Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos. 1995 ; 23 (1). 28-34.
5. Burton M., Shaw L., Schentag JJ, Evans WE Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring, 4 th ed. Philidelphia, PA: Lippincott Williams and Wilkins ; 2005: 530-552.
6. Michalets EL Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998 ; 18 (1). 84-112.
7. McLaughlin GE, Rossique-Gonzalez M., Gelman B., et al. Use of phenobarbital in the management of acute tacrolimus toxicity. Transplant Proc. 2000 ; 32 (3). 665-668.
8. Karasu Z., Gurakar A., Carlson J., et al. Acute tacrolimus overdose and treatment with phenytoin in liver transplant recipients. J Okla State Med Assoc. 2001 ; 94 (4). 121-123.
9. Wada K., Takada M., Sakai M., et al. Drug interaction between tacrolimus and carbamazepine in a Japanese heart transplant recipient: a case report. J Heart Lung Transplant. 2009 ; 28 (4). 409-411.
10. Schweitzer EJ, Canafax DM, Gillingham KJ, et al. Phenytoin administration in renal allograft recipients on cyclosporine administration. Clin Transplant. 1993 ; 7: 9-13.
11. Danovitch, G. Handbook of Kidney Transplantation, 3 rd ed. Philidelphia, PA: Lippincott Williams and Wilkins ; 2001: 75-82.
12. Dai Y., Hebert MF, Isoherranen N., et al. Effect of CYP3A5 polymorphisms on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006 ; 34 (5). 836-847.
13. Haufroid V., Wallemacq P., VanKerckhove V., et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant. 2006 ; 6 (11). 2706-2713.
14. Chabolla DR, Harnois DM, Meschia JF Levetiracetam monotherapy for liver transplant patients with seizures. Transplant Proc. 2003 ; 35 (4). 1480-1481.
15. Theodore WH, Porter RJ, Raubertas RF Seizures during barbiturate withdrawal: relation to blood level. Ann Neurol. 1987 ; 22 (5). 644-647.
16. Nelson E., Powell JR, Conrad K., et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol. 1982 ; 22 (2-3). 141-148.